Algorithme Pharma, a member of Altasciences, is an established early stage clinical contract research organization (CRO) providing research services for pharmaceutical, biotechnology and generic drug industries.
Our facilities include a 7-unit clinic with 265 beds and a 20,000 square foot Bioanalytical laboratory. We successfully complete over 200 clinical trials annually in Phase I/IIa and Bioequivalence.
Moderator: Dr. Marc Lefebvre, Vice-President Scientific & Regulatory Affairs, Algorithme Pharma
By incorporating patients effectively and efficiently into early phase clinical trials, sponsors can accelerate their timelines by up to 3 to 5 months, decrease development risk as key drug information is obtained earlier and reduce the overall project costs. This webinar will present a Phase I clinical trial case study which evaluates the impact of four Renal Impairment stage levels on the investigational drug’s pharmacokinetic characteristics. Algorithme Pharma managed the complete project, assessed stages one and two of the clinical trial and through a formal alliance had stages three and four conducted at a Hospital (HMR) who have Nephrology expertise.
Impaired Renal Function Clinical Trials: Data Sheet
The First-in-Human (FIH) clinical trial model developed by Algorithme Pharma, improves timelines and cost-savings while preserving result integrity and patient safety. Experienced with Therapeutic Area patient populations, our focus is effectively channeled in planning study design to fit a sponsor’s programme.
Customize in Real-Time: First-In-Human (FIH) Trial Gantt Chart
Try our complimentary First-In-Human (FIH) Trial Web App designed to help in the planning of early stage clinical timelines